Granite Point Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Granite Point Capital Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-1,196	Closed	-$403K	–	103
2014 Q2	$403K	Sell	1,196 -133	-10%	-$52.2K	0.28%	70
2014 Q1	$591K	Sell	1,329 -1,600	-55%	-$726K	0.42%	72
2013 Q4	$1.31M	Buy	+2,929	New	+$1.28M	0.22%	50

Other funds holding DMK

Grow Partners San Diego, California $4.81M AUM 7.86% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Granite Point Capital Management's DMK Position: Q3 2014 in Review

Granite Point Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2014, closing a stake of 1,196 shares — an estimated $403K sold.

Granite Point Capital Management first reported a position in DMK in Q4 2013 and held it in 3 quarters. The position peaked at $1.31M in Q4 2013. 19 funds tracked by Wall St. Rank hold DMK as of Q3 2014.

Granite Point Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2014 after selling out during the quarter.
Granite Point Capital Management sold 1,196 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2014, an estimated $403K.
Granite Point Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 3 quarters.
Granite Point Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $1.31M in Q4 2013.
19 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2014.

Based on Granite Point Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.